The IDH1 Knouckout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, featuring targeted disruption of the IDH1 gene. This product provides a genetically heterogeneous pool of cells with IDH1 loss-of-function, enabling robust investigation of gene function without the clonal biases associated with single-cell isolates. The polyclonal format maintains the diverse mutational profile generated by CRISPR/Cas9 editing, making it a versatile tool for studying IDH1-dependent processes in a disease-relevant cellular context. Researchers can exploit this model to explore metabolic reprogramming and oxidative stress responses in liver cancer, as the knockout population collectively recapitulates the consequences of IDH1 deficiency.
SK-HEP-1 cells are an immortalized human hepatic adenocarcinoma cell line widely employed in liver cancer research due to their tumorigenic properties and relevance to hepatocellular carcinoma and other hepatic malignancies. Established from the ascites of a patient with adenocarcinoma, these cells exhibit a hybrid endothelial and epithelial phenotype, facilitating studies on tumor microenvironment interactions and metastasis. SK-HEP-1 cells are particularly suitable for investigating metabolic adaptations in cancer, as they retain functional pathways for glycolysis, glutaminolysis, and oxidative phosphorylation, making them a well-characterized platform for assessing the impact of IDH1 knockout on cellular energetics and redox homeostasis.
IDH1 encodes the cytosolic isocitrate dehydrogenase 1 enzyme, which catalyzes the oxidative decarboxylation of isocitrate to ??-ketoglutarate with concomitant reduction of NADP+ to NADPH. This reaction is a critical source of NADPH for lipid biosynthesis and antioxidant defense, and it intersects with epigenetic regulation by generating ??-ketoglutarate, a cofactor for TET enzymes and histone demethylases. IDH1 functions as a homodimer and is activated by metabolic stress signals and hypoxia, partly through HIF-1??-mediated transcriptional regulation. Downstream, IDH1 influences the availability of ??-ketoglutarate and NADPH, thereby modulating TET2-dependent DNA demethylation and maintaining redox balance. Wild-type IDH1 prevents the accumulation of the oncometabolite 2-hydroxyglutarate, which is associated with mutant IDH1 in glioblastoma and AML.
In the SK-HEP-1 hepatic adenocarcinoma background, IDH1 knockout disrupts a key metabolic node, leading to diminished NADPH production and heightened vulnerability to oxidative stress. This loss-of-function model mimics aspects of IDH1 deficiency observed in certain cancers and metabolic disorders, enabling dissection of how cytosolic IDH1 activity maintains redox equilibrium and supports anabolic pathways. The polyclonal knockout population provides an experimentally tractable system to evaluate the interplay between IDH1-driven metabolism, tumor cell survival, and epigenetic regulation, particularly in the liver where IDH1 is highly expressed. Consequently, these cells offer a relevant platform for exploring IDH1 as a therapeutic target and for studying compensatory mechanisms that arise in the absence of wild-type enzymatic function.
Typical research applications include mechanistic studies of cancer metabolism, where IDH1 knockout cells can be subjected to metabolomics profiling, NADPH/NADP+ ratio measurements, and IDH1 enzyme activity assays to quantify metabolic rewiring. The model is ideal for oxidative stress investigations, employing ROS measurement and cell viability assays under hypoxia or drug-induced stress to assess the knockout phenotype. Additionally, these cells enable functional genomics screens, drug sensitivity testing, and phenotypic analyses such as migration and invasion assays, facilitating the identification of synthetic lethal interactions or novel therapeutic strategies. For further details on experimental design using the IDH1 Knouckout SK-HEP-1 Polyclonal Cells, please contact Ascent Research.
